Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00391,Sulpiride
,22100559,flow rate,"Mobile phase (acetonitrile-0.01 M phosphate buffer pH=3, flow rate 1 ml min(-1)) in the gradient mode was employed in the HPLC analysis.",High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22100559/),[ml] / [min],1,14743,DB00391,Sulpiride
,22100559,λ(exc.)/λ(emiss.),"Low concentrations of tiapride and N-desethyl tiapride were determined using a more selective fluorescence detector (λ(exc.)/λ(emiss.)=232 nm/334 nm), high concentrations (500-6000 pmol ml(-1)) using a UV PDA detector at 212 nm with a linear response.",High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22100559/),,232,14744,DB00391,Sulpiride
,22100559,recoveries,"The recoveries of tiapride ranged from 89.3 to 94.3%, 81.7 to 86.8% for internal standard sulpiride and 90.9 to 91.8% for N-desethyl tiapride.",High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22100559/),%,89.3 to 94.3,14745,DB00391,Sulpiride
,22100559,recoveries,"The recoveries of tiapride ranged from 89.3 to 94.3%, 81.7 to 86.8% for internal standard sulpiride and 90.9 to 91.8% for N-desethyl tiapride.",High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22100559/),%,81.7 to 86.8,14746,DB00391,Sulpiride
,22100559,recoveries,"The recoveries of tiapride ranged from 89.3 to 94.3%, 81.7 to 86.8% for internal standard sulpiride and 90.9 to 91.8% for N-desethyl tiapride.",High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22100559/),%,90.9 to 91.8,14747,DB00391,Sulpiride
,27184677,C max,"The optimized XePoMas formulation was shown to increase intestinal absorption of sulpiride to a greater extent than the marketed product in vivo, with a C max of 830.58 ng/mL after 15 h.",In Vivo Evaluation of a PEO-Gellan Gum Semi-Interpenetrating Polymer Network for the Oral Delivery of Sulpiride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184677/),[ng] / [ml],830.58,24222,DB00391,Sulpiride
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,2.6,25394,DB00391,Sulpiride
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,68,25395,DB00391,Sulpiride
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,40,25396,DB00391,Sulpiride
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,60,25397,DB00391,Sulpiride
,28499878,Km,"Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM.","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,18,25398,DB00391,Sulpiride
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.22,29064,DB00391,Sulpiride
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.020,29065,DB00391,Sulpiride
,26404395,AUC0-t,"The corresponding mean AUC0-t increased from 449 to 1443 ng/h/mL and from 2874 to 7559 ng/h/mL, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),[ng] / [h·ml],449 to 1443,31327,DB00391,Sulpiride
,26404395,AUC0-t,"The corresponding mean AUC0-t increased from 449 to 1443 ng/h/mL and from 2874 to 7559 ng/h/mL, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),[ng] / [h·ml],2874 to 7559,31328,DB00391,Sulpiride
,26404395,accumulation index,"After repeated PO and IM administration, steady state was reached on day 4 of multiple dosing with accumulation index of 1.8 and on day 2 of multiple dosing with accumulation index of 1.3, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),,1.8,31329,DB00391,Sulpiride
,26404395,accumulation index,"After repeated PO and IM administration, steady state was reached on day 4 of multiple dosing with accumulation index of 1.8 and on day 2 of multiple dosing with accumulation index of 1.3, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),,1.3,31330,DB00391,Sulpiride
,26404395,bioavailability,"The bioavailability of levosulpiride via IM and PO routes was 96.8% and 23.4%, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),%,96.8,31331,DB00391,Sulpiride
,26404395,bioavailability,"The bioavailability of levosulpiride via IM and PO routes was 96.8% and 23.4%, respectively.","Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26404395/),%,23.4,31332,DB00391,Sulpiride
,546899,sensitivity,The sensitivity is 2 microgram in a 1-ml sample (amount applied 30 ng) for sulpiride and related compounds and about the same for vincamine.,"[Quantitative determination of drugs by in situ spectrophotometry of chromatograms for pharmacokinetic studies. I. Sulpiride and other benzamides, vincamine, naftazone (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/546899/),μg,2,32423,DB00391,Sulpiride
,15315786,recoveries,"The recoveries of levosulpiride ranged from 80.5 to 87.4%, with that of tiapride (internal standard) being 84.6%.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315786/),%,80.5 to 87.4,33014,DB00391,Sulpiride
,15315786,recoveries,"The recoveries of levosulpiride ranged from 80.5 to 87.4%, with that of tiapride (internal standard) being 84.6%.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315786/),%,84.6,33015,DB00391,Sulpiride
,96745,plasma t1/2,The plasma t1/2 was 8.3 hr.,Metabolism of sulpiride in man and rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/96745/),h,8.3,33815,DB00391,Sulpiride
,24469600,half-life,"At fasting state, amisulpride reached the first peak (37.1 ± 13.3 ng/ml) at ~2.3 h, and decreased down to 19.4 ± 4.3 ng/ml until 3.5 h, and then again went up to the second peak (25.3 ± 5.8 ng/ml) at 5 h followed by a slow decay with 10.6 h of half-life.",Prandial effect on the systemic exposure of amisulpride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,10.6,37200,DB00391,Sulpiride
,24469600,maximum concentration,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),[ng] / [ml],56.0,37201,DB00391,Sulpiride
,24469600,time to peak,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,1.7,37202,DB00391,Sulpiride
,1566638,maximal serum concentrations,"The maximal serum concentrations were 506.1 ng/ml +/- 87.2 (S.D.) and 509.1 ng/ml +/- 101.9 (S.D.) for Sulpiride and Dogmatil fort, respectively.",[In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1566638/),[ng] / [ml],506.1,54710,DB00391,Sulpiride
,1566638,maximal serum concentrations,"The maximal serum concentrations were 506.1 ng/ml +/- 87.2 (S.D.) and 509.1 ng/ml +/- 101.9 (S.D.) for Sulpiride and Dogmatil fort, respectively.",[In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1566638/),[ng] / [ml],509.1,54711,DB00391,Sulpiride
,1566638,half-life,The half-life of Sulpiride in serum was 9.9 hr +/- 1.3 (S.D.) following dosing with Dogmatil fort tablet and 12.2 hr +/- 3.0 (S.D.) following dosing with Sulpiride tablet.,[In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1566638/),h,9.9,54712,DB00391,Sulpiride
,1566638,half-life,The half-life of Sulpiride in serum was 9.9 hr +/- 1.3 (S.D.) following dosing with Dogmatil fort tablet and 12.2 hr +/- 3.0 (S.D.) following dosing with Sulpiride tablet.,[In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1566638/),h,12.2,54713,DB00391,Sulpiride
,8852049,limit of quantitation (LOQ),The limit of quantitation (LOQ) in human plasma is 2.5 ng ml-1 for both S-(-)- and R-(+)-amisulpride isomers with both detection methods.,"Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852049/),[ng] / [ml],2.5,57548,DB00391,Sulpiride
,541409,detection limit,The detection limit was about 10 ng/ml in serum and cerebrospinal fluid and about 200 ng/ml in urine.,Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/541409/),[ng] / [ml],10,57918,DB00391,Sulpiride
,541409,detection limit,The detection limit was about 10 ng/ml in serum and cerebrospinal fluid and about 200 ng/ml in urine.,Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/541409/),[ng] / [ml],200,57919,DB00391,Sulpiride
,541409,half-life,The half-life for sulpiride in serum was about 8 h.,Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/541409/),h,8,57920,DB00391,Sulpiride
,31206720,bioavailability,The IM mean bioavailability was 66.97%.,Pharmacokinetics of levosulpiride after single-dose administration in goats (Capra hircus) by different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206720/),%,66.97,64419,DB00391,Sulpiride
,31206720,bioavailability,"After PO administration, the drug plasma concentrations were detectable only in the time range 1.5-4 hr, and the bioavailability (4.73%) was low.",Pharmacokinetics of levosulpiride after single-dose administration in goats (Capra hircus) by different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206720/),%,4.73,64420,DB00391,Sulpiride
,28196046,ke,ke and t1/2 were 0.07 (SD: 0.02) and 9 hours (8-12) for both the formulations.,Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196046/),h,0.07,81352,DB00391,Sulpiride
,28196046,t1/2,ke and t1/2 were 0.07 (SD: 0.02) and 9 hours (8-12) for both the formulations.,Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196046/),h,9,81353,DB00391,Sulpiride
,28196046,Clearance,"Clearance (L/h) was 29.6 (±13.5) and 30.7 (±14.2) for the test and the reference product, respectively.",Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196046/),[l] / [h],29.6,81354,DB00391,Sulpiride
,28196046,Clearance,"Clearance (L/h) was 29.6 (±13.5) and 30.7 (±14.2) for the test and the reference product, respectively.",Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196046/),[l] / [h],30.7,81355,DB00391,Sulpiride
,1869345,Cmax,"The Cmax of the test preparation showed therapeutically relevant plasma concentrations of greater than 400 ng/ml, compared with about 300 ng/ml for the reference preparation.",The importance of pharmacokinetic data on sulpiride: results of a bioequivalence study of two sulpiride 200 mg preparations following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869345/),[ng] / [ml],300,82459,DB00391,Sulpiride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.0,84478,DB00391,Sulpiride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,5,84479,DB00391,Sulpiride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.1,84480,DB00391,Sulpiride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,2,98969,DB00391,Sulpiride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,1.5,98970,DB00391,Sulpiride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,3,98971,DB00391,Sulpiride
,4049901,half-life,In man mean serum levels of unchanged drug attained a peak at 1.5 h and were eliminated with a half-life of 3.6 h.,"Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,3.6,98972,DB00391,Sulpiride
,33291402,hardness,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),kp,4.58,101330,DB00391,Sulpiride
,33291402,friability,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),%,0.73,101331,DB00391,Sulpiride
,33291402,disintegration time,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),s,37.5,101332,DB00391,Sulpiride
,33291402,drug release,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),%,100.51,101333,DB00391,Sulpiride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),[ng] / [ml],71,112312,DB00391,Sulpiride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,65,112313,DB00391,Sulpiride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,67,112314,DB00391,Sulpiride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,52,112315,DB00391,Sulpiride
,28334978,D2/3,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112316,DB00391,Sulpiride
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112317,DB00391,Sulpiride
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,25,112318,DB00391,Sulpiride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,61,112319,DB00391,Sulpiride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,49,112320,DB00391,Sulpiride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,69,112321,DB00391,Sulpiride
,16252067,area under concentration-time curve,"Accordingly, the area under concentration-time curve in serum and brain was higher in CsA co-treated rats (13.5 vs.",Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252067/),,13.5,116658,DB00391,Sulpiride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],19.5,119038,DB00391,Sulpiride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],"5,188",119039,DB00391,Sulpiride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],266,119040,DB00391,Sulpiride
,23585286,k,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.079,132331,DB00391,Sulpiride
,23585286,t1/2,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),h,9.0,132332,DB00391,Sulpiride
,23585286,Vd /F,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),l,330.5,132333,DB00391,Sulpiride
,23585286,Cl/F,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),[l] / [h],38.2,132334,DB00391,Sulpiride
,23585286,AUC0→∞,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),[h·ng] / [ml],1402.5,132335,DB00391,Sulpiride
,23585286,k21,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.68,132336,DB00391,Sulpiride
,23585286,ka1,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.7,132337,DB00391,Sulpiride
,23585286,ka2,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],2.7,132338,DB00391,Sulpiride
,23585286,Vc/F,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),l,45.1,132339,DB00391,Sulpiride
,23585286,α,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],33.3,132340,DB00391,Sulpiride
,23585286,β,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.11,132341,DB00391,Sulpiride
,23585286,time for the beginning of,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),h,4.4,132342,DB00391,Sulpiride
,19488984,retention times,The retention times of levosulpiride (0.63 min) and IS (0.66 min) presented a significant time saving benefit of the proposed method.,Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488984/),min,0.63,134113,DB00391,Sulpiride
,19488984,retention times,The retention times of levosulpiride (0.63 min) and IS (0.66 min) presented a significant time saving benefit of the proposed method.,Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488984/),min,0.66,134114,DB00391,Sulpiride
,6491918,lowest detectable concentration,The lowest detectable concentration was 10 ng/mL.,Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[ng] / [ml],10,137403,DB00391,Sulpiride
,6491918,apparent half-lives of the absorption,"Plasma concentration versus time and urinary excretion rate versus time curves were consistent with an open two-compartment body model, where mean +/- SD apparent half-lives of the absorption from muscle, lambda 1 distribution, and lambda 2 elimination phases were 6.96 +/- 2.64 min, 0.220 +/- 0.120 h, and 6.74 +/- 2.67 h, respectively.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),min,6.96,137404,DB00391,Sulpiride
,6491918,apparent half-lives of the absorption,"Plasma concentration versus time and urinary excretion rate versus time curves were consistent with an open two-compartment body model, where mean +/- SD apparent half-lives of the absorption from muscle, lambda 1 distribution, and lambda 2 elimination phases were 6.96 +/- 2.64 min, 0.220 +/- 0.120 h, and 6.74 +/- 2.67 h, respectively.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),h,0.220,137405,DB00391,Sulpiride
,6491918,apparent half-lives of the absorption,"Plasma concentration versus time and urinary excretion rate versus time curves were consistent with an open two-compartment body model, where mean +/- SD apparent half-lives of the absorption from muscle, lambda 1 distribution, and lambda 2 elimination phases were 6.96 +/- 2.64 min, 0.220 +/- 0.120 h, and 6.74 +/- 2.67 h, respectively.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),h,6.74,137406,DB00391,Sulpiride
,6491918,volume of distribution,"The initial volume of distribution was 0.145 +/- 0.063 L/kg, the steady-state volume of distribution was 0.639 +/- 0.184 L/kg, and the total clearance was 89.8 +/- 22.3 mL/min.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[l] / [kg],0.145,137407,DB00391,Sulpiride
,6491918,steady-state volume of distribution,"The initial volume of distribution was 0.145 +/- 0.063 L/kg, the steady-state volume of distribution was 0.639 +/- 0.184 L/kg, and the total clearance was 89.8 +/- 22.3 mL/min.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[l] / [kg],0.639,137408,DB00391,Sulpiride
,6491918,total clearance,"The initial volume of distribution was 0.145 +/- 0.063 L/kg, the steady-state volume of distribution was 0.639 +/- 0.184 L/kg, and the total clearance was 89.8 +/- 22.3 mL/min.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[ml] / [min],89.8,137409,DB00391,Sulpiride
,6491918,k12,"The microscopic rate constants were k12 = 2.53 +/- 1.13 h-1, k21 = 0.674 +/- 0.197 h-1, and k10 = 0.635 +/- 0.298 h-1.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),1/[h],2.53,137410,DB00391,Sulpiride
,6491918,k21,"The microscopic rate constants were k12 = 2.53 +/- 1.13 h-1, k21 = 0.674 +/- 0.197 h-1, and k10 = 0.635 +/- 0.298 h-1.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),1/[h],0.674,137411,DB00391,Sulpiride
,6491918,k10,"The microscopic rate constants were k12 = 2.53 +/- 1.13 h-1, k21 = 0.674 +/- 0.197 h-1, and k10 = 0.635 +/- 0.298 h-1.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),1/[h],0.635,137412,DB00391,Sulpiride
,6491918,total clearance,"Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and renal clearance of unbound drug (97.6 mL/min, f = 0.15) indicated that sulpiride is mainly excreted unchanged by the renal route, 93.1 +/- 6.6% of the administered dose being recovered unchanged in urine.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[ml] / [min],89.8,137413,DB00391,Sulpiride
,6491918,renal clearance,"Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and renal clearance of unbound drug (97.6 mL/min, f = 0.15) indicated that sulpiride is mainly excreted unchanged by the renal route, 93.1 +/- 6.6% of the administered dose being recovered unchanged in urine.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[ml] / [min],83.0,137414,DB00391,Sulpiride
,6491918,renal clearance of unbound drug,"Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and renal clearance of unbound drug (97.6 mL/min, f = 0.15) indicated that sulpiride is mainly excreted unchanged by the renal route, 93.1 +/- 6.6% of the administered dose being recovered unchanged in urine.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),[ml] / [min],97.6,137415,DB00391,Sulpiride
,6491918,f,"Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and renal clearance of unbound drug (97.6 mL/min, f = 0.15) indicated that sulpiride is mainly excreted unchanged by the renal route, 93.1 +/- 6.6% of the administered dose being recovered unchanged in urine.",Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491918/),,0.15,137416,DB00391,Sulpiride
,16386474,peak plasma concentration (C(max)),A peak plasma concentration (C(max)) of 522.58 ng/ml was achieved after 3.55 h (t(max)).,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ng] / [ml],522.58,139920,DB00391,Sulpiride
,16386474,t(max),A peak plasma concentration (C(max)) of 522.58 ng/ml was achieved after 3.55 h (t(max)).,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),h,3.55,139921,DB00391,Sulpiride
,16386474,areas under the plasma concentration-time curve (AUC),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3405.35,139922,DB00391,Sulpiride
,16386474,AUC(0-infinity),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3405.35,139923,DB00391,Sulpiride
,16386474,AUC(0-tlast),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3306.54,139924,DB00391,Sulpiride
,16386474,terminal plasma elimination half-life (t(1/2)),The terminal plasma elimination half-life (t(1/2)) was 10.36 h.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),h,10.36,139925,DB00391,Sulpiride
,7418717,total distribution volume during the terminal slope,The average total distribution volume during the terminal slope was 2.72 +/- 0.66 l/kg and total systemic clearance was 415 +/- 84 ml/min.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),[l] / [kg],2.72,140995,DB00391,Sulpiride
,7418717,total systemic clearance,The average total distribution volume during the terminal slope was 2.72 +/- 0.66 l/kg and total systemic clearance was 415 +/- 84 ml/min.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),[ml] / [min],415,140996,DB00391,Sulpiride
,7418717,serum half-life of the terminal slope,The serum half-life of the terminal slope following intravenous administration averaged 5.3 h (range 3.7--7.1 h) according to the two-compartment model.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),h,5.3,140997,DB00391,Sulpiride
,7418717,half-lives,In two subjects the half-lives were 11.0 and 13.9 h when the three-compartment model was applied.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),h,11.0,140998,DB00391,Sulpiride
,7418717,half-lives,In two subjects the half-lives were 11.0 and 13.9 h when the three-compartment model was applied.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),h,13.9,140999,DB00391,Sulpiride
,7418717,half-life,Determinations of urinary excretion rates of unchanged sulpiride indicated a half-life of 7.15 h.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),h,7.15,141000,DB00391,Sulpiride
,7418717,renal clearance,"Following intravenous administration, 70 +/- 9% of the dose was recovered unchanged in urine within 36 h; the mean renal clearance was 310 +/- 91 ml/min.",The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),[ml] / [min],310,141001,DB00391,Sulpiride
,7418717,renal clearance,"The recovery of unchanged drug in urine following oral administration was 15 +/- 5% of the dose, with a mean renal clearance of 223 +/- 47 ml/min.",The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),[ml] / [min],223,141002,DB00391,Sulpiride
,7418717,bioavailability,The bioavailability determined from combined plasma and urine data was only 27 +/- 9%.,The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418717/),%,27,141003,DB00391,Sulpiride
,12404702,bioavailability,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,48,142126,DB00391,Sulpiride
,12404702,protein binding,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,17,142127,DB00391,Sulpiride
,12404702,elimination half-life,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),h,12,142128,DB00391,Sulpiride
,31478760,en,"The optimised SUL microsponges showed a yield of 79.82 ± 2.37%, an encapsulation efficiency of 89.11 ± 2.28% and in vitro time for floatation of 8.0 h.","Sulpiride gastro-retentive floating microsponges; analytical study, in vitro optimization and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31478760/),%,89.11,144506,DB00391,Sulpiride
,31478760,time for floatation,"The optimised SUL microsponges showed a yield of 79.82 ± 2.37%, an encapsulation efficiency of 89.11 ± 2.28% and in vitro time for floatation of 8.0 h.","Sulpiride gastro-retentive floating microsponges; analytical study, in vitro optimization and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31478760/),h,8.0,144507,DB00391,Sulpiride
,16324716,plasma levels,Patients with EPS (14.6%) had significantly (P<0.05) higher amisulpride plasma levels (377+/-290 ng/ml) than patients without EPS (305+/-274 ng/ml) despite similar doses in both groups (595+/-266 vs. 594+/-246 mg).,Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16324716/),[ng] / [ml],377,146373,DB00391,Sulpiride
,16324716,plasma levels,Patients with EPS (14.6%) had significantly (P<0.05) higher amisulpride plasma levels (377+/-290 ng/ml) than patients without EPS (305+/-274 ng/ml) despite similar doses in both groups (595+/-266 vs. 594+/-246 mg).,Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16324716/),[ng] / [ml],305,146374,DB00391,Sulpiride
,14581065,absolute recovery,The mean absolute recovery for human serum was 89.8+/-3.7%.,Improvement and validation of a liquid chromatographic method for the determination of levosulpiride in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581065/),%,89.8,156872,DB00391,Sulpiride
,4030988,detection limit,The detection limit in plasma and RBC was 10 ng/ml for sulpiride and 15 ng/ml for sultopride.,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),[ng] / [ml],10,164665,DB00391,Sulpiride
,4030988,detection limit,The detection limit in plasma and RBC was 10 ng/ml for sulpiride and 15 ng/ml for sultopride.,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),[ng] / [ml],15,164666,DB00391,Sulpiride
,4030988,Half-lives,Half-lives determined from either plasma or RBC concentrations were similar (7 h for sulpiride and 5 h for sultopride).,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),h,7,164667,DB00391,Sulpiride
,4030988,Half-lives,Half-lives determined from either plasma or RBC concentrations were similar (7 h for sulpiride and 5 h for sultopride).,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),h,5,164668,DB00391,Sulpiride
,2129121,oral bioavailability,4. The oral bioavailability of gludopa is only 1 to 2% and this rules out the dipeptide as an effective dopaminergic prodrug.,Five years' experience with gamma-L-glutamyl-L-dopa: a relatively renally specific dopaminergic prodrug in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129121/),%,1 to 2,168601,DB00391,Sulpiride
,3800511,absolute bioavailability,The absolute bioavailability after oral administration was only about 15% which was also the level after intraduodenal administration.,Gastrointestinal absorption of sulpiride in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800511/),%,15,172315,DB00391,Sulpiride
,543747,Bioavailability,Bioavailability of the oral hydrochloride solution was 85% and that of the free base suspension was 75%.,Bioavailability of 14C-sulpiride in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543747/),%,85,175969,DB00391,Sulpiride
,543747,Bioavailability,Bioavailability of the oral hydrochloride solution was 85% and that of the free base suspension was 75%.,Bioavailability of 14C-sulpiride in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543747/),%,75,175970,DB00391,Sulpiride
,543747,apparent volume of distribution,Sulpiride equilibrated rapidly with tissue fluid and had an apparent volume of distribution of 3.3--3.8 1/kg.,Bioavailability of 14C-sulpiride in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543747/),[1] / [kg],3.3,175971,DB00391,Sulpiride
,543747,plasma half-life,The plasma half-life was 2.5--3 hours.,Bioavailability of 14C-sulpiride in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543747/),h,2.5,175972,DB00391,Sulpiride
,25501871,bioavailability,"Sulpiride SD-incorporated witepsol H15 formulation showed acceptable in vitro characteristics with a bioavailability of 117% relative to oral dosing, which excel that in humans (27% after dosing of oral product).",Pediatric suppositories of sulpiride solid dispersion for treatment of Tourette syndrome: in vitro and in vivo investigations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25501871/),%,117,178819,DB00391,Sulpiride
,25501871,bioavailability,"Sulpiride SD-incorporated witepsol H15 formulation showed acceptable in vitro characteristics with a bioavailability of 117% relative to oral dosing, which excel that in humans (27% after dosing of oral product).",Pediatric suppositories of sulpiride solid dispersion for treatment of Tourette syndrome: in vitro and in vivo investigations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25501871/),%,27,178820,DB00391,Sulpiride
,1815069,apparent elimination half-life,"After iv administration, the mean +/- SD apparent elimination half-life of sulpiride was 6.47 +/- 1.00 h, and the mean +/- SD volume of distribution at steady state was 0.94 +/- 0.23 L/kg.",Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),h,6.47,183239,DB00391,Sulpiride
,1815069,volume of distribution at steady state,"After iv administration, the mean +/- SD apparent elimination half-life of sulpiride was 6.47 +/- 1.00 h, and the mean +/- SD volume of distribution at steady state was 0.94 +/- 0.23 L/kg.",Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),[l] / [kg],0.94,183240,DB00391,Sulpiride
,1815069,Renal clearance,Renal clearance (119.5 +/- 28.2 mL/min) was very close to total clearance (127.8 +/- 26.2 mL/min).,Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),[ml] / [min],119.5,183241,DB00391,Sulpiride
,1815069,total clearance,Renal clearance (119.5 +/- 28.2 mL/min) was very close to total clearance (127.8 +/- 26.2 mL/min).,Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),[ml] / [min],127.8,183242,DB00391,Sulpiride
,1815069,recovery,"In urine, the mean +/- SD recovery in form of the unchanged drug was 90.0 +/- 9.68% of the administered dose, and the excretion rate versus time showed an elimination half-life similar to that found in plasma.",Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),%,90.0,183243,DB00391,Sulpiride
,1815069,partition coefficient,"The sulpiride partition coefficient between RBC and plasma did not show any significant change as a function of time and concentration, with a mean value +/- SD of 1.00 +/- 0.043, indicating that sulpiride is evenly distributed between RBC and plasma.",Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815069/),,1.00,183244,DB00391,Sulpiride
,2769828,maximal concentration (Cmax),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcg] / [ml],1.468,188654,DB00391,Sulpiride
,2769828,maximal concentration (Cmax),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcg] / [ml],1.472,188655,DB00391,Sulpiride
,2769828,time to reach maximal concentration (Tmax),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),h,1.5,188656,DB00391,Sulpiride
,2769828,time to reach maximal concentration (Tmax),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),h,1.25,188657,DB00391,Sulpiride
,2769828,half life (T 1/2),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),h,8.369,188658,DB00391,Sulpiride
,2769828,half life (T 1/2),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),h,8.013,188659,DB00391,Sulpiride
,2769828,area under curve (from 0 to 24 hours) (AUC0-24 hr),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcghr] / [ml],11.03,188660,DB00391,Sulpiride
,2769828,area under curve (from 0 to 24 hours) (AUC0-24 hr),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcghr] / [ml],8.27,188661,DB00391,Sulpiride
,2769828,area under curve (from 0 hour to infinity) (AUC0-hr),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcghr] / [ml],13.56,188662,DB00391,Sulpiride
,2769828,area under curve (from 0 hour to infinity) (AUC0-hr),"The results revealed that the maximal concentration (Cmax) of Dogmatyl and the generic preparation was 1.468 +/- 0.631 and 1.472 +/- 0.608 mcg/ml, the time to reach maximal concentration (Tmax) was 1.5 +/- 0.63 and 1.25 +/- 0.61 hours, the half life (T 1/2) was 8.369 +/- 1.953 and 8.013 +/- 2.602 hours, the area under curve (from 0 to 24 hours) (AUC0-24 hr) was 11.03 +/- 6.78 and 8.27 +/- 2.99 mcghr/ml, and the area under curve (from 0 hour to infinity) (AUC0-hr) was 13.56 +/- 9.09 and 10.11 +/- 4.61 mcghr/ml, respectively.",[Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769828/),[mcghr] / [ml],10.11,188663,DB00391,Sulpiride
,28793958,AUC<sub>0-tlast</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup>],"4,767.2",190834,DB00391,Sulpiride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup>],"4,856.3",190835,DB00391,Sulpiride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup],"4,891.7",190836,DB00391,Sulpiride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup],"5,043.2",190837,DB00391,Sulpiride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],584.7,190838,DB00391,Sulpiride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],586.3,190839,DB00391,Sulpiride
,28793958,C<sub>max</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],586.3,190840,DB00391,Sulpiride
,28793958,relative bioavailability,The relative bioavailability was 98.9 ± 14.5%.,Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),%,98.9,190841,DB00391,Sulpiride
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],6.1,191086,DB00391,Sulpiride
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],15.6,191087,DB00391,Sulpiride
,999405,peak concentrations,"The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[μg] / [ml],23.9,191088,DB00391,Sulpiride
,999405,half-life,"The half-life of sulpiride in dog plasma (1.6 -- 3.4 hr) is longer than that of metoclopramide, but in the rat there is little difference between the two compounds.",Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),h,1,191089,DB00391,Sulpiride
,999405,total apparent volumes of distribution,Both of the compounds have large total apparent volumes of distribution (1-2 1/kg) in the two species.,Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999405/),[1] / [kg],1-2,191090,DB00391,Sulpiride
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],33,196011,DB00391,Sulpiride
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],46,196012,DB00391,Sulpiride
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],4,196013,DB00391,Sulpiride
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],86,196014,DB00391,Sulpiride
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],93,196015,DB00391,Sulpiride
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],9,196016,DB00391,Sulpiride
,1981028,o,"The octanol-water partition coefficients of the base of 1(2) and sulpiride were 6.3 and 0.2, respectively.","Comparative pharmacokinetics of sulpiride and N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride, a new lipophilic substituted benzamide in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981028/),,6.3,196999,DB00391,Sulpiride
,1981028,o,"The octanol-water partition coefficients of the base of 1(2) and sulpiride were 6.3 and 0.2, respectively.","Comparative pharmacokinetics of sulpiride and N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride, a new lipophilic substituted benzamide in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981028/),,0.2,197000,DB00391,Sulpiride
,1981028,systemic bioavailabilities,"The systemic bioavailabilities of 1 and sulpiride after oral administration of 200 mg/kg were 60.9 +/- 10.9 and 18.2 +/- 6.4%, respectively.","Comparative pharmacokinetics of sulpiride and N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride, a new lipophilic substituted benzamide in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981028/),%,60.9,197001,DB00391,Sulpiride
,1981028,systemic bioavailabilities,"The systemic bioavailabilities of 1 and sulpiride after oral administration of 200 mg/kg were 60.9 +/- 10.9 and 18.2 +/- 6.4%, respectively.","Comparative pharmacokinetics of sulpiride and N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride, a new lipophilic substituted benzamide in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981028/),%,18.2,197002,DB00391,Sulpiride
,1981028,brain/plasma ratios,The brain/plasma ratios of 2 were about 2 times higher than those of sulpiride.,"Comparative pharmacokinetics of sulpiride and N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride, a new lipophilic substituted benzamide in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981028/),,2,197003,DB00391,Sulpiride
,7337503,apparent half life,"Serum sultopride levels reached peak 1 hr after the administration and declined with an apparent half life of 3.5 hr, while serum sulpiride levels increased gradually and the high serum level at 2 hr remained for up to 6 hr.",Development of radioimmunoassay for sultopride and sulpiride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337503/),h,3.5,197324,DB00391,Sulpiride
,1619566,fraction of dose absorbed,The fraction of dose absorbed after oral administration was approximately 30% based on plasma and urine data.,"Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619566/),%,30,205948,DB00391,Sulpiride
,1619566,elimination half-life,"After the 200-mg dose, the mean elimination half-life was 7.0 h, and the mean residence time was 8.4 h.","Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619566/),h,7.0,205949,DB00391,Sulpiride
,1619566,mean residence time,"After the 200-mg dose, the mean elimination half-life was 7.0 h, and the mean residence time was 8.4 h.","Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619566/),h,8.4,205950,DB00391,Sulpiride
,18562411,C/D ratios,"Mean amisulpride doses (574 +/- 269 mg/day), plasma levels (304 +/- 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 +/- 0.41 ng/mL:mg), clinical response (at least moderate improvement, 71.6%), and side effects (any side effect, 32.2%; extrapyramidal symptoms, 14.9%) were comparable between age groups (P > 0.25).",Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18562411/),[ng] / [ml:mg],0.52,207735,DB00391,Sulpiride
,18655221,run time,A run time of 2.0 min for each sample made it possible to analyze more than 275 human plasma samples per day.,Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 microL of plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655221/),min,2.0,211122,DB00391,Sulpiride
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.41,212065,DB00391,Sulpiride
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.60,212066,DB00391,Sulpiride
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],64.1,221765,DB00391,Sulpiride
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],56,221766,DB00391,Sulpiride
,9754984,t1/2,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),h,15.6,221767,DB00391,Sulpiride
,9754984,AUC,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),ng,667,221768,DB00391,Sulpiride
,3760094,detection limit,"The detector response was linear from 10 to 1000 ng/ml and the detection limit was 10 ng/ml, which is sensitive enough for pharmacokinetic studies.",Improved determination of sulpiride in plasma by ion-pair liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760094/),[ng] / [ml],10,246453,DB00391,Sulpiride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.94,250000,DB00391,Sulpiride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.62,250001,DB00391,Sulpiride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.26,250002,DB00391,Sulpiride
